Articles Vol. 66 No. CĐ14-HNKH BV Giao thông Vận tải 12/01/2026

30. STEM CELL AND STEM CELL-DERIVED PRODUCTS IN OPHTHALMIC DISEASES: AN UPDATED REVIEW, 2020–2025

Pham Xuan Da1,2,3, Ngo Chi Thanh3, Ngo Tuan Minh4, Pham Tue Lien5
1 University of Medicine and Pharmacy - Vietnam National University, Hanoi
2 Trường đại học Y dược - Đại học quốc gia Hà Nội
3 Bệnh viện Giao thông vận tải
4 Khoa Y, Trường Kinh doanh và Công nghệ Hà Nội
5 Bệnh viện Mắt Quốc tế Nhật Bản
Corresponding author: drdavn@gmail.com
DOI: 10.52163/yhc.v66iCD14.3083
22 Views
65 Downloads
Keywords
Stem cells; extracellular vesicles (exosomes); retina; cornea.
Abstract

Objective: To review the application of stem cell therapies and stem cell-derived products in ophthalmic diseases.

Methods: A narrative review was conducted using PubMed and Google Scholar. Clinical studies published between 2020–2025 on the efficacy, safety, and clinical outcomes of stem cell therapies and extracellular vesicle (exosome) products were analyzed.

Results: ESC/iPSC-derived RPE transplantation for late-stage dry AMD showed long-term safety and visual improvement. In LSCD, CALEC achieved 77% complete success at 18 months, while allogeneic SLET maintained epithelialization in 71% of cases at 12 months. Intrastromal ADSC injection improved vision and corneal curvature in keratoconus. MSC-derived exosomes and eye drops improved dry eye indices with good safety. In glaucoma, early studies suggested neuroprotective effects on retinal ganglion cells.

Conclusions: Current evidence supports the safety and potential efficacy of stem cell-based therapies in ophthalmology. However, larger trials with long-term follow-up are needed to confirm durable benefits.

References
[1]
Humayun MS, Clegg DO, Dayan MS, et al. Long‑term Follow‑up of a Phase 1/2a Clinical Trial of a Stem Cell‑Derived Bioengineered Retinal Pigment Epithelium Implant for Geographic Atrophy. Ophthalmology. 2024;131(6):682‑691. doi:10.1016/j.ophtha.2023.12.028. Google Scholar
[2]
Kashani AH, Lebkowski JS, Rahhal FM, et al. One‑Year Follow‑Up in a Phase 1/2a Clinical Trial of an Allogeneic RPE Cell Bioengineered Implant for Advanced Dry AMD. Transl Vis Sci Technol. 2021;10(10):13. Google Scholar
[3]
Kashani AH, Uang J, Mert M, et al. Surgical method for implantation of a biosynthetic RPE monolayer for geographic atrophy: experience from a phase 1/2a study. Ophthalmol Retina. 2020;4(3):264‑273. Google Scholar
[4]
California Institute for Regenerative Medicine (CIRM). Phase 2/3 pivotal planning for jCell (famzeretcel) after FDA Type B meeting (January 2024) – progress update. 2024. (Grant progress page). Google Scholar
[5]
Jurkunas UV, Qi X, Suri K, et al. Cultivated autologous limbal epithelial cell (CALEC) transplantation for limbal stem cell deficiency: a phase I/II clinical trial with xenobiotic‑free, serum‑free, antibiotic‑free manufacturing. Nat Commun. 2025; (ấn hành trực tuyến). Google Scholar
[6]
Riedl J, Mais C, Langenbucher A, et al. Midterm results after allogeneic simple limbal epithelial transplantation from deceased‑donor eyes in LSCD. Acta Ophthalmol. 2025;103(2):e—e. (PMCID: PMC11810538). Google Scholar
[7]
Ramin S, Ahadi M, Abbasi A, et al. Intrastromal injection of adipose‑derived stem cells in keratoconus: a pilot study. Int J Ophthalmol. 2023;16(6):949‑957. Google Scholar
[8]
Habibi A, Khosravi A, Soleimani M, et al. Efficacy of topical mesenchymal stem cell exosome in Sjögren’s syndrome‑related dry eye: randomized triple‑blind clinical trial. BMC Ophthalmol. 2025;25:299. Google Scholar
[9]
Zhang D, Chen T, Liang Q, et al. First‑in‑human prospective pilot trial of umbilical cord‑derived MSC eye drops for refractory dry eye disease. Stem Cell Res Ther. 2025;16:202. Google Scholar
[10]
Hu BY, Zhou L, Li Y, et al. Mesenchymal stem cells for repairing glaucomatous optic nerve injury: advances and controversies. (Review). 2024. Google Scholar
[11]
Ji S, Zhao H, Lyu P, et al. Human adipose tissue‑derived stem cell extracellular vesicles alleviate neuroinflammation in ocular hypertension models. Acta Neuropathol Commun. 2024;12. Google Scholar
[12]
Pastor JC, Rusciano D, Delgado A, et al. Intravitreal allogeneic mesenchymal stem cells: safety considerations and clinical insights. 2023. (Review). Google Scholar
[13]
Soundararajan P, et al. Allogeneic retinal pigment epithelial cell suspension manufactured at scale for AMD. npj Regen Med. 2025;10. Google Scholar
[14]
Jiao YR, Chen KX, Tang X, et al. Exosomes derived from mesenchymal stem cells in diabetes and diabetic complications. Cell Death Dis. 2024;15:271. Google Scholar
[15]
Durmaz E, et al. Utilizing extracellular vesicles as a drug delivery system in the eye. J Control Release. 2024. Google Scholar
[16]
Rohowetz LJ, et al. Gene and cell therapies currently used and in development for AMD and IRDs. Front Ophthalmol. 2023;3:1098406. Google Scholar
[17]
Liu H, Xu T, Wang J, et al. Advances in retinal pigment epithelial cell transplantation for retinal degenerative diseases. Stem Cell Res Ther. 2024. Google Scholar
[18]
Klymenko V, et al. Recent progress in RPE cell‑based therapy for retinal degeneration. 2024. Google Scholar
[19]
Wang LH, et al. Advances in neuroprotection in glaucoma: role of cell‑based and exosome strategies. Pharmaceuticals (Basel). 2024;17(10):1261. Google Scholar
[20]
Lin F, et al. Tackling visual impairment: emerging avenues in retinal neuroprotection and cell therapy. 2025. Google Scholar